In response to the COVID-19 global pandemic, the largest mass vaccination campaign on record was initiated. In the United States, the Pfizer-BioNTech BNT162b2 (https://www.pfizer.com/science/coronavirus/vaccine/manufacturing-and-distribution) and Moderna mRNA-1273 (https://www.wsj.com/articles/moderna-to-build-vaccine-manufacturing-plant-in-africa-11633586400) messenger RNA (mRNA) vaccines received Emergency Use Authorization in December 2020.⁽¹⁾ Because patients who were immunosuppressed, including liver transplantation recipients (LTRs), were excluded from these vaccine trials, the safety and efficacy of COVID-19 vaccination in LTRs are largely unknown. Herein, we report a case of acute inflammatory demyelinating polyneuropathy (AIDP), the most common subtype of Guillain-Barré syndrome (GBS), following an initial dose of an mRNA COVID-19 vaccine in an adult LTR. Case studies such as ours defined as “experiences or observations associated with one or two individuals” are exempt from institutional review board approval at the University of Michigan.

为了应对 COVID-19 全球大流行，发起了有记录以来最大规模的大规模疫苗接种运动。在美国，Pfizer-BioNTech BNT162b2 (https://www.pfizer.com/science/coronavirus/vaccine/manufacturing-and-distribution) 和 Moderna mRNA-1273 (https://www.wsj.com/articles /moderna-to-build-vaccine-manufacturing-plant-in-africa-11633586400) 信使 RNA (mRNA) 疫苗于 2020 年 12 月获得紧急使用授权。^{( 1 )}由于免疫抑制患者（包括肝移植受者 (LTR)）被排除在这些疫苗试验之外，因此在 LTR 中接种 COVID-19 疫苗的安全性和有效性在很大程度上是未知的。在此，我们报告了一例急性炎症性脱髓鞘性多发性神经病 (AIDP)，这是格林-巴利综合征 (GBS) 最常见的亚型，在成人 LTR 中接受初始剂量的 mRNA COVID-19 疫苗后。像我们这样的案例研究被定义为“与一两个人相关的经验或观察”，不受密歇根大学机构审查委员会的批准。